Ampicillin

證據等級: L5

預測適應症: 10 個

Ampicillin: From Bacterial Infections to Laryngitis

One-Sentence Summary

Ampicillin is a broad-spectrum penicillin-class antibiotic with established use for a wide range of bacterial infections, including respiratory, urinary tract, and gastrointestinal infections. The TxGNN model predicts it may be effective for Laryngitis, with 1 clinical trial and 20 publications currently supporting this direction. The supporting evidence is predominantly indirect and retrospective, placing this prediction at an early exploratory stage requiring further investigation before clinical application.

Quick Overview

Item	Content
Original Indication	Broad-spectrum bacterial infections (respiratory, urinary tract, gastrointestinal)
Predicted New Indication	Laryngitis
TxGNN Prediction Score	99.97%
Evidence Level	L3
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Ampicillin is a penicillin-class β-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), rendering it active against a broad spectrum of Gram-positive and some Gram-negative organisms. Its antibacterial action is therefore mechanistically plausible against bacterial causes of laryngeal infections.

Bacterial laryngitis and its more severe form, acute epiglottitis, are commonly caused by pathogens such as Haemophilus influenzae type b and Streptococcus pyogenes — organisms against which ampicillin theoretically retains activity. Historical clinical literature documents ampicillin use in the management of acute epiglottitis (PMID 3977063, PMID 5314768), providing retrospective indirect support for the TxGNN prediction. The mechanistic overlap between laryngeal infections and other upper respiratory bacterial infections already treated with β-lactam antibiotics further strengthens the biological plausibility.

However, a critical clinical limitation must be noted: the progressive global rise of β-lactamase-producing H. influenzae strains — now exceeding 50% in many regions — has substantially eroded ampicillin’s real-world effectiveness for upper airway infections. Contemporary international guidelines (WHO, IDSA) no longer recommend ampicillin monotherapy for suspected bacterial epiglottitis or laryngitis, instead favouring third-generation cephalosporins or amoxicillin/clavulanate. Any potential use of ampicillin for this indication would therefore need to be guided by local microbiological susceptibility data.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01406275	N/A	Completed	363	Post-marketing surveillance of CLAVAMOX® (amoxicillin/clavulanate) paediatric dry syrup in Japanese children with multiple upper respiratory indications explicitly including laryngitis, pharyngitis, tonsillitis, acute bronchitis, and skin infections (excluding otitis media). Provides indirect safety and efficacy data from a related β-lactam/inhibitor combination in a laryngitis-inclusive real-world paediatric population.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39879424	2025	Clinical Guideline Quality Assessment	CoDAS	Systematic appraisal of existing clinical guidelines for laryngitis and pharyngitis management using the AGREE II tool; identifies methodological gaps in current evidence-based guidance.
3977063	1985	Retrospective Case Series	Anaesthesia and Intensive Care	Review of 161 children admitted with acute epiglottitis over 10 years; 45 complications in 34 patients including 5 deaths. Ampicillin documented as historical treatment agent. Preferred airway approach is direct laryngoscopy with nasotracheal intubation under general anaesthesia.
6465636	1984	Case Series	Annals of Emergency Medicine	Three adult cases of acute epiglottitis; symptoms disproportionate to pharyngeal findings with dysphagia and anterior neck tenderness. All had benign outcomes; diagnosis confirmed by fiberoptic laryngoscopy.
5314768	1971	Historical Case Series	British Medical Journal	Early historical documentation of adult epiglottitis; penicillin-class antibiotics used as primary treatment, establishing the first evidence base for β-lactam use in laryngeal infections.
35923122	2023	Case Report + Literature Review	Ann Otol Rhinol Laryngol	Novel case of spontaneous laryngeal abscess in uncontrolled diabetes; comprehensive review of modern reported cases. Notes that laryngeal abscesses are rare in the antibiotic era but remain life-threatening when they occur.
34986973	2023	Case Report	Auris Nasus Larynx	COVID-19 presenting as acute epiglottitis with necrotic laryngeal lesions in a 44-year-old male; underscores importance of recognising atypical causes of laryngeal inflammation and the need for prompt airway management.
38145982	2024	Retrospective Cohort	Eur Arch Otorhinolaryngol	Analysis of pathogen distribution and antibiotic selection in neck abscesses among diabetic vs non-diabetic patients; provides current data on antimicrobial susceptibility patterns relevant to deep laryngeal space infections.
12402494	2002	Case Series	Acta Otorrinolaringol Esp	Two cases of paraglottic space laryngeal abscesses; emphasises rapid diagnosis and urgent treatment requirement given the life-threatening nature of this rare entity.
30579693	2019	Case Report	Auris Nasus Larynx	Laryngeal actinomycosis following bone marrow transplantation in an immunocompromised 14-year-old girl; penicillin-class antibiotic used for definitive treatment after histological diagnosis.
25944348	2015	Retrospective Cohort	Otolaryngol Head Neck Surg	Hospital- and physician-level variation in perioperative antibiotic choice for laryngectomy; demonstrates that choice of β-lactam antibiotic class is associated with differences in surgical site infection and wound dehiscence rates.

South Africa Market Information

Ampicillin is currently not registered with SAHPRA and has no active product licences in South Africa. No Essential Medicines List (EML) inclusion data is available for this product in the current evidence pack.

Note for healthcare professionals: Ampicillin is widely available internationally and is included on the WHO Essential Medicines List. Any clinical use in South Africa would require confirmation of registration status or appropriate regulatory authorisation. Consult SAHPRA (www.sahpra.org.za) for the current status of any ampicillin-containing products.

Safety Considerations

No SAHPRA-specific safety data (warnings, contraindications, or drug interactions) was available in this evidence pack. Please refer to an internationally recognised prescribing reference (e.g., WHO Model Formulary, British National Formulary, or the manufacturer’s approved Professional Information) for complete safety information.

Key safety considerations known from the international literature include:

Hypersensitivity reactions: Ranging from maculopapular rash to anaphylaxis; cross-reactivity with other penicillins and partial cross-reactivity with cephalosporins. A history of severe penicillin allergy is a contraindication.
Infectious mononucleosis (glandular fever) rash: Ampicillin and amoxicillin are associated with a high rate of maculopapular rash in patients with Epstein-Barr virus (EBV) infection. These agents should be avoided in suspected glandular fever — a clinically important concern given that EBV pharyngitis/laryngitis can mimic bacterial infection.
Antibiotic-associated diarrhoea: Including Clostridioides difficile-associated disease, particularly with prolonged or repeated courses.
Resistance and treatment failure: Widespread β-lactamase-producing organisms (including H. influenzae, S. aureus, and Enterobacteriaceae) limit clinical utility without prior susceptibility testing.

Report adverse drug reactions to SAHPRA via MedErr online reporting at www.sahpra.org.za.

Conclusion and Next Steps

Decision: Hold

Rationale: Ampicillin has a mechanistically plausible basis for treating bacterial laryngitis and epiglottitis, supported by historical retrospective literature (L3 evidence). However, Ampicillin is currently not registered in South Africa, the drug has no SAHPRA-approved Professional Information available for this indication, and the substantial rise in β-lactamase-producing upper respiratory pathogens across Sub-Saharan Africa means that empirical ampicillin monotherapy for laryngitis is unlikely to be clinically reliable without susceptibility-guided prescribing. Well-established alternatives (amoxicillin/clavulanate, third-generation cephalosporins) are recommended by current international guidelines.

To proceed, the following is needed:

Local susceptibility data: South African or regional (Sub-Saharan Africa) microbiological data on β-lactamase rates among laryngitis/epiglottitis pathogens (H. influenzae, S. pyogenes) to determine whether ampicillin resistance profiles permit empirical use
SAHPRA registration review: Assessment of whether any ampicillin-containing product holds or can obtain SAHPRA registration; confirmation of regulatory pathway for procurement
MOA documentation: Retrieval of complete DrugBank pharmacology data (mechanism, targets, pharmacokinetics) to enable formal mechanistic gap analysis
SAHPRA Professional Information (PI): Download and review of the approved PI or equivalent international SPC for complete warnings, contraindications, and dosing information
Direct clinical evidence: Prospective or controlled clinical data specifically evaluating ampicillin for bacterial laryngitis; current evidence base relies entirely on indirect retrospective sources
Consideration of combination therapy: If ampicillin is to be explored further, evaluation of ampicillin-sulbactam combination (which restores activity against β-lactamase producers) would be more clinically relevant than ampicillin monotherapy

⚠️ Disclaimer: This report is generated for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any clinical application. All prescribing decisions must comply with SAHPRA-approved labelling and current South African treatment guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.